Back to results
US 2021/0330683 A1Published application
Compositions and methods for enhanced delivery of antiviral agents
AssigneePoviva Corp.
InventorsJohn Docherty, Christopher Andrew Bunka
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.
Claims20
A pharmaceutical composition, comprising:
- a) one or more antiviral agents chosen from protease inhibitors, endonuclease inhibitors, integrase inhibitors, enzyme inhibitors, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, cell entry inhibitors, mRNA and protein synthesis inhibitors cannabinoids, viral replication blockers, uncoating inhibitors, reverse transcriptase inhibitors, topoisomerase inhibitors, assembly inhibitors, M2 inhibitors, DNA polymerase inhibitors, DNA terminase complex inhibitors, HCV protein inhibitors, neuraminidase inhibitors, or virus-neutralizing antibodies;
- and
- b) a bioavailability enhancing agent chosen from palm kernel oil, soybean oil, rapeseed oil (canola), sunflower oil, groundnut oil, sesame oil, flaxseed oil, palm oil, olive oil or corn oil.
A pharmaceutical composition, comprising:
- i) from about 5% to about 20% by weight of an active base, comprising:
- a) from about 25% to about 50% by weight of one or more antiviral agents;
- b) from about 50% to about 75% by weight of a bioavailability enhancing agent;
- and
- ii) from about 50% to about 70% gum arabic;
- iii) the balance carriers and other adjunct ingredients.
3 more elements
A method for treating a subject having a viral infection comprising, administering to a person infected with a virus an effective amount of a composition comprising:
- a) one or more antiviral agents chosen from protease inhibitors, endonuclease inhibitors, integrase inhibitors, enzyme inhibitors, non-nucleoside reverse transcriptase inhibitors, fusion inhibitors, cell entry inhibitors, mRNA and protein synthesis inhibitors cannabinoids, viral replication blockers, uncoating inhibitors, reverse transcriptase inhibitors, topoisomerase inhibitors, assembly inhibitors, M2 inhibitors, DNA polymerase inhibitors, DNA terminase complex inhibitors, HCV protein inhibitors, neuraminidase inhibitors, or virus-neutralizing antibodies;
- and
- b) a bioavailability enhancing agent chosen from palm kernel oil, soybean oil, rapeseed oil (canola), sunflower oil, groundnut oil, sesame oil, flaxseed oil, palm oil, olive oil or corn oil.
Dependencies are inferred from the claim text.